Cancer clinical trials in the region Île-de-France

578 currently recruiting clinical trials

Looking for clinical trials?

Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:

Create your account
Copy-paste your latest medical report
Our AI-based assistant does the rest for you

Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:

Create your account
and find trials relevant to your profile

Early Access Lung cancer

Accès précoce pré-AMM– TAGRISSO (Osimertinib)

NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced EGFR None Chemotherapy Radiotherapy

AstraZeneca

Early Access Lymphoma

Accès précoce post-AMM – COLUMVI (Glofitamab)

B cell lymphoma Large B cell lymphoma 2 3 or more

Systemic Treatment-Naive

Hoffmann-La Roche

Early Access Lung cancer

Accès précoce pré-AMM– IMFINZI (Durvalumab)

SCLC (Small Cell Lung Cancer) Localized Locally Advanced None Chemotherapy Radiotherapy Chemotherapy Radiotherapy

AstraZeneca

Early Access Lung cancer

Accès précoce pré-AMM– RYBREVANT (Amivantamab)

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR None Systemic Treatment-Naive

Janssen

Early Access Lung cancer

Accès précoce pré-AMM– RYBREVANT (Amivantamab)

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR 1 Targeted therapy

Systemic Treatment-Naive

Janssen

Early Access Lymphoma

Accès précoce post-AMM – COLUMVI (Glofitamab)

B cell lymphoma Large B cell lymphoma 1

Systemic Treatment-Naive

Hoffmann-La Roche

Phase 3 Colon cancer Rectal cancer #NCT06662786 #2024-513852-13-00

[OrigAMI-2] Étude de l'AMIVANTAMAB et du mFOLFOX6 ou du FOLFIRI par rapport au CETUXIMAB et au mFOLFOX6 ou au FOLFIRI comme traitement de première intention chez les participants atteints d'un cancer colorectal gauche non résécable ou métastatique de type sauvage KRAS/NRAS et BRAF

Locally Advanced Metastatic None Systemic Treatment-Naive

BRAF HER2 KRAS G12C KRAS non G12C MSI/dMMR NRAS

Gustave Roussy (Villejuif), Hôpital Saint Antoine AP-HP (Paris)

Janssen

Phase 3 Stomach and esophageal cancer #NCT06731478 #2024-513122-27-00

[Destiny-Gastric05] Étude du TRASTUZUMAB DERUXTECAN, de la CHIMIOTHERAPIE, du PEMBROLIZUMAB et du TRASTUZUMAB dans le traitement du cancer de l'estomac ou de la jonction gastro-œsophagienne métastatique HER2-positif en première intention

Stomach Oesogastric junction Adenocarcinoma Locally Advanced Metastatic HER2 None Systemic Treatment-Naive

Targeted therapy Targeted therapy

Hôpital Saint Antoine AP-HP (Paris), Institut Mutualiste Montsouris (Paris), Hôpital Foch (Suresnes)

Daiichi Sankyo

Phase 3 Lung cancer #NCT04928846 #2023-505749-14-00

[TeliMet] TELISOTUZUMAB VÉDOTIN vs DOCÉTAXEL chez des patients atteints d'un cancer du poumon non à petites cellules non épidermoïde (CBNPC) précédemment traité, surexprimant c-MET

NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic MET 1 Immunotherapy Chemotherapy Targeted therapy

EGFR Systemic Treatment-Naive Antibody Drug Conjugates (ADC)

Centre Hospitalier Intercommunal Créteil (Créteil Cedex), Gustave Roussy (Villejuif), Hôpital Tenon AP-HP (Paris ), Hôpital Cochin (Paris ), Institut Curie - Paris (Paris)

Abbvie

Phase 3 Head and neck cancer #NCT06064877

Étude du ficlatuzumab en association avec le cétuximab chez des participants atteints d'un carcinome épidermoïde de la tête et du cou récidivant ou métastatique (R/M) HPV négatif

Oral cavity Nasopharynx Oropharynx Hypopharynx Larynx Salivary glands Nasal cavities and sinuses Other Squamous cell carcinoma Locally Advanced Metastatic 1 2 Immunotherapy Chemotherapy

Systemic Treatment-Naive

Gustave Roussy (Villejuif), Institut Curie - Paris (Paris)

AVEO Pharmaceuticals, Inc.